Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus lenalidomide versus lenalidomide maintenance after autologous stem cell transplant in newly diagnosed multiple myeloma
ACTRN12620000291987Phase 3Terminated
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of selinexor and lenalidomide in multiple myeloma (MM), sponsored by Australasian Leukaemia & Lymphoma Group. Started Jan 2021; status: terminated.
02
Drugs
selinexorlenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12620000291987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000291987.